<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
        xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-news/0.9 http://www.google.com/schemas/sitemap-news/0.9/sitemap-news.xsd http://www.google.com/schemas/sitemap-image/1.1 https://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd">
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904310228-merakris-therapeutics-provides-fda-update-and-reports-interim-findings-for-mtx-001-in-venous-leg-ulcers</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:30:00+00:00</news:publication_date>
        <news:title>Merakris Therapeutics Provides FDA Update and Reports Interim Findings for MTX-001 in Venous Leg Ulcers</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/5b9c5fed-3332-4d4d-b8b6-6ab1b15faaed/small/mrks-brand-logo-final-fullcolor-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904310391-nurexone-biologic-s-u-s-subsidiary-exo-top-and-florida-based-bioxtek-sign-strategic-loi-for-exosome-manufacturing-and-commercialization</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:18:00+00:00</news:publication_date>
        <news:title>NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/1514c671-cc84-4bcb-82d7-b834fce40882/small/nurexone-logo-rebrand-large-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904308717-cellution-biologics-inc-announces-official-entry-into-the-ocular-market-at-ascrs-with-the-launch-of-opticover</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:11:00+00:00</news:publication_date>
        <news:title>Cellution Biologics Inc. Announces Official Entry into the Ocular Market at ASCRS with the Launch of OptiCover™</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/10957e60-6696-483a-9df0-88f8713da811/medium/opticover.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904309254-srx-health-solutions-returns-5-69-in-march-2026-driven-by-emjx-artificial-intelligence-ai-engine</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:05:00+00:00</news:publication_date>
        <news:title>SRx Health Solutions Returns +5.69% in March 2026 Driven by EMJX Artificial Intelligence (AI) Engine</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/768807fe-a29b-48f5-be44-977c8eaf49f0/small/srxlogo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904310171-medx-holdings-reports-strong-q4-results-achieves-net-profitability-and-announces-strategic-partnerships-to-supercharge-franchise-expansion</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:05:00+00:00</news:publication_date>
        <news:title>MEDX HOLDINGS REPORTS STRONG Q4 RESULTS, ACHIEVES NET PROFITABILITY, AND ANNOUNCES STRATEGIC PARTNERSHIPS TO SUPERCHARGE FRANCHISE EXPANSION</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/995733cb-620f-4ea6-b204-8b5b5689df30/small/medx-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904310583-treace-announces-first-surgical-cases-with-the-superbite-compression-screw-system</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:04:29+00:00</news:publication_date>
        <news:title>Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/6f3a2631-2457-4100-950a-3dec602ec68d/medium/superbite-compression-screw-system.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904308778-saladax-biomedical-to-expand-international-access-to-drug-level-testing-for-psychiatry-and-oncology</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:00:00+00:00</news:publication_date>
        <news:title>Saladax Biomedical to Expand International Access to Drug Level Testing for Psychiatry and Oncology</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/M2NiMWYwYzAtNjA1My00OWFiLWFkN2ItZjY5YzgxNjE4MzI3LTUwMDEyNDYwOC0yMDI2LTA0LTA3LWVu/tiny/Saladax-Biomedical-Inc-.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904308956-pathai-and-medstar-health-announce-partnership-to-deploy-the-aisight-dx-digital-pathology-platform-and-advanced-ai-applications</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:00:00+00:00</news:publication_date>
        <news:title>PathAI and MedStar Health Announce Partnership to Deploy the AISight® Dx Digital Pathology Platform and Advanced AI Applications</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/ab2bfc12-ae80-47c6-9345-a98783489ed7/small/pathai-logo-standard-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904309046-death-by-a-thousand-vendors-81-of-employers-are-hiring-just-to-keep-up-with-digital-health-vendor-sprawl</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:00:00+00:00</news:publication_date>
        <news:title>Death by a Thousand Vendors: 81% of Employers Are Hiring Just to Keep Up with Digital Health Vendor Sprawl</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/b8d88974-2aeb-4baa-ad3b-2ab758ed4dd9/small/solera-main-logo-red-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904309197-lumin-health-appoints-matthew-mosquera-md-ms-as-regional-medical-director-and-site-director-of-lumin-cambridge</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:00:00+00:00</news:publication_date>
        <news:title>Lumin Health Appoints Matthew Mosquera, MD, MS, as Regional Medical Director and Site Director of Lumin Cambridge</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/cb31fc23-dea3-476e-971b-6265973b0739/medium/matthew-mosquera.jpeg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904310148-ai-and-online-health-information-are-booming-but-americans-don-t-fully-trust-what-they-find</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T13:00:00+00:00</news:publication_date>
        <news:title>AI and Online Health Information Are Booming, But Americans Don’t Fully Trust What They Find</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/NjE3YzhiYjItN2E5Yy00MjE5LWI1YTQtMGUzMmVlZjY3NzM2LTUwMDE2MDA3Mi0yMDI2LTA0LTA3LWVu/tiny/American-Association-of-Nurse-.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904309350-outlook-therapeutics-announces-formal-dispute-resolution-request-for-ons-5010-lytenava-bevacizumab-vikg-accepted-by-fda</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:50:00+00:00</news:publication_date>
        <news:title>Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/cbff3302-f8d2-466a-beff-8c33252f9c70/small/otlk-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904309225-vivos-therapeutics-completes-private-placement-with-existing-private-equity-investor-new-seneca-partners</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:45:00+00:00</news:publication_date>
        <news:title>Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/22d07f60-2e17-421d-bbc3-748c2402061e/small/picture2-jpg.JPG</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904308798-moleculin-releases-next-ceo-corner-segment-highlighting-annamycin-s-non-cardiotoxic-profile</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:36:00+00:00</news:publication_date>
        <news:title>Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/7fa09722-2ef8-49fc-bc24-6b150093f8ba/small/mbrx-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299971-20-20-biolabs-selected-by-evexia-diagnostics-to-offer-onetest-for-cancer-through-evexia-platform</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:31:00+00:00</news:publication_date>
        <news:title>20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/bcaf95ca-9983-408c-bc61-646e4ee2f925/small/2020-biolabs-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299756-xenon-to-highlight-phase-3-x-tole2-long-term-data-for-azetukalner-in-focal-onset-seizures-at-2026-aan-annual-meeting</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:30:00+00:00</news:publication_date>
        <news:title>Xenon to Highlight Phase 3 X-TOLE2 &amp; Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/505b89d3-dfd1-46e8-bc3b-3c9c699ef7ec/small/xenon-logo-tm-full-color-250x80px-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299796-abeona-therapeutics-announces-appointment-of-keith-a-goldan-to-its-board-of-directors</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:30:00+00:00</news:publication_date>
        <news:title>Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299918-clover-health-empowers-members-to-take-charge-of-their-health-data-through-healthex-partnership</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:30:00+00:00</news:publication_date>
        <news:title>Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/1a48a25b-b654-4d62-adb3-d1a776346264/small/clover-logo-green-rgb-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299951-integra-lifesciences-unveils-new-real-world-evidence-highlighting-primatrix-utilization</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:30:00+00:00</news:publication_date>
        <news:title>Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/00cf1e29-7492-4f89-bab1-6691cf2253c4/medium/primatrix-dermal-scaffold.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299992-ss-innovations-to-host-smrsc-2026-in-new-delhi-india-from-april-9-11-2026</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:30:00+00:00</news:publication_date>
        <news:title>SS Innovations to Host SMRSC 2026 in New Delhi, India from April 9-11, 2026</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/cef267e0-040f-4889-a706-cc4d0ae49e55/small/new-logo-april-23-2025-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300074-cormedix-to-participate-in-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:30:00+00:00</news:publication_date>
        <news:title>CorMedix to Participate in Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/a14d732c-3f66-4a3c-96bb-7fc8ba5797bb/small/crmd-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300165-milestone-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:30:00+00:00</news:publication_date>
        <news:title>Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/49b2e16b-2deb-4c9e-9c20-6cc4fd6c15ab/small/milestone-pharmaceuticals-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300233-cdt-notes-sarborg-publication-of-prism-framework-expanding-ai</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:30:00+00:00</news:publication_date>
        <news:title>CDT Notes Sarborg Publication of PRISM Framework Expanding AI</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/MjNiMmZlYjctZjk3NS00MWViLThkMjktZWUwZGQ1YzVkNzRjLTEyNzQxMDItMjAyNi0wNC0wNy1lbg==/tiny/CDT-Equity-Inc-.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299831-biorestorative-therapies-announces-strategic-collaboration-with-203-creates-to-build-and-commercialize-biocosmeceutical-platform</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:15:00+00:00</news:publication_date>
        <news:title>BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/a9a09a16-9f91-466d-a0b4-2a7f2fd05ebe/small/logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299713-nextcure-receives-fast-track-designation-for-sim0505-cdh6-adc-in-ovarian-cancer</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:05:00+00:00</news:publication_date>
        <news:title>NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/df24cd65-0f3d-4ede-9e7a-c3f58ce6e9d4/small/logo-nextcure-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300472-emergent-biosolutions-launches-new-narcan-nasal-spray-carrying-case-and-multipacks-alongside-college-campus-outreach-to-expand-opioid-overdose</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:05:00+00:00</news:publication_date>
        <news:title>Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/3fcbfc65-93d7-475f-9f23-b47fbf2ab8ca/medium/narcan-nasal-spray-multipacks.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299511-evaxion-announces-last-patient-visit-in-one-year-extension-of-phase-2-trial-with-personalized-cancer-vaccine-evx-01</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299601-lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/fa4a7bb1-f8ea-45e7-ba51-37077689a4fb/small/lyell-branding-color-rgb-102918a-copy-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299705-inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/32b8d8bc-ebf8-43c0-866a-6613b22263b1/small/ikt-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299752-amneal-announces-2-million-donation-to-support-patient-access-to-essential-medicines-during-parkinson-s-awareness-month</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/a20d6f40-90af-422f-ab14-47208fdbad2f/small/amneal-rgb-k-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299830-crispr-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/5dac7d0d-131d-4047-bab7-db8e0719bf58/small/crispr-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299833-gatc-health-and-uc-irvine-announce-landmark-pnas-publication-validating-ai-platform-for-opioid-use-disorder-treatment</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>GATC Health and UC Irvine Announce Landmark PNAS Publication Validating AI-Platform for Opioid Use Disorder Treatment</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/8252f5cc-6aca-4b39-b708-845c0ce98b86/small/color-logo-vector-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299835-solid-biosciences-to-participate-at-upcoming-investor-conferences</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Solid Biosciences to Participate at Upcoming Investor Conferences</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/bb5e6b30-d9d9-464f-8c64-33a09eacc3fb/small/solid-1029x579-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299849-valitor-announces-oral-presentation-at-the-upcoming-association-for-research-in-vision-and-ophthalmology-arvo-2026-annual-meeting</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Valitor Announces Oral Presentation at the Upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/58da3c80-c616-4358-9bbe-2936ace96649/small/valitor-sidebyside-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299853-route-92-medical-announces-50-million-growth-financing</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Route 92 Medical Announces $50 Million Growth Financing</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/526036da-ddbe-4a9a-9222-9570f7cd6544/small/r-rt92-logo-rbg0-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299871-akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299961-aclarion-highlights-growing-adoption-of-nociscan-at-the-london-clinic-with-new-physician-video</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300025-calidi-biotherapeutics-announces-speaker-presentation-at-asgct-conference-in-boston-on-may-14-2026-highlighting-the-redtail-platform-s-ability-to</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300073-corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300089-liquidia-corporation-to-participate-in-upcoming-investor-conferences</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Liquidia Corporation to Participate in Upcoming Investor Conferences</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/f7659070-cc55-4e68-ae70-33013e7df72c/small/liquidia-new-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300151-electrocore-announces-first-patient-enrollment-in-investigator-led-study-of-gammacore-nvns-for-ptsd</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/b80ed5b6-a449-461c-9034-85386286b09d/small/ec-logo-2018-tm-cmyk-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300354-jupiter-neurosciences-appoints-kristopher-fishman-and-sanjiv-lal-to-nugevia-advisory-board</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/4e829d7e-ecf6-46ad-98fe-479755d626e1/small/image-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300403-polyrizon-ltd-announces-3-5-million-registered-direct-offering-and-private-placement</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T12:00:00+00:00</news:publication_date>
        <news:title>Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/N2M3NTE1MmItYWFmMi00MDNlLWE4MTItMWIxMDg4MWYwMTRlLTUwMDEyOTIyMy0yMDI2LTA0LTA3LWVu/tiny/Polyrizon-Ltd-.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300175-artelo-biosciences-regains-compliance-with-nasdaq-listing-requirements</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:50:00+00:00</news:publication_date>
        <news:title>Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/460502d7-b0d3-43d8-a15a-5b2bb963bbbb/small/artelo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299627-marvel-biosciences-secures-financial-and-strategic-investment-with-5-horizon-ventures</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:30:00+00:00</news:publication_date>
        <news:title>Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/d49e32dc-88d9-4694-a3dd-6e663548e80d/small/picture1-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299632-anavex-life-sciences-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:30:00+00:00</news:publication_date>
        <news:title>Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299759-everbright-health-announces-ai-enabled-platform-to-unlock-access-to-advanced-mental-health-interventions</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:30:00+00:00</news:publication_date>
        <news:title>Everbright Health Announces AI-Enabled Platform to Unlock Access to Advanced Mental Health Interventions</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/2ce4a623-23ed-4e51-9115-db1f2526bcfc/small/everbrighthealth-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299841-plus-therapeutics-receives-ama-pla-code-for-cnside-csf-tumor-cell-enumeration-test-advancing-reimbursement-and-u-s-commercial-adoption</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:30:00+00:00</news:publication_date>
        <news:title>Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904299993-cognition-therapeutics-to-present-at-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:30:00+00:00</news:publication_date>
        <news:title>Cognition Therapeutics to Present at Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/a14fd627-7ccb-45e2-95fe-792bbfb83231/small/2020-0227-cognition-logo-for-gnw-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300070-palvella-therapeutics-appoints-accomplished-commercial-leader-kent-taylor-as-senior-vice-president-of-sales</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:30:00+00:00</news:publication_date>
        <news:title>Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300109-cervomed-to-provide-neflamapimod-clinical-program-update-and-participate-in-a-panel-on-biomarkers-at-2026-lewy-body-dementia-association-annual</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:30:00+00:00</news:publication_date>
        <news:title>CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/332fd58e-5e2b-4c96-8eaf-719ac2e34f52/small/cervomed-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300157-nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-on-restore-a-phase-3-registrational-study-of-nvg-291-for-chronic</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:30:00+00:00</news:publication_date>
        <news:title>NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904300328-weight-watchers-appoints-lisa-gavales-and-sue-gove-to-board-of-directors</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:30:00+00:00</news:publication_date>
        <news:title>Weight Watchers Appoints Lisa Gavales and Sue Gove to Board of Directors</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/f435b439-7f75-4d2f-a6cc-0e4e2ed811ea/small/weightwatchers-wordmark-boldblue-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290412-pluristyx-extends-patent-portfolio-in-universal-cell-therapy-with-new-u-s-patent-for-iact-stealth-technology</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:09:00+00:00</news:publication_date>
        <news:title>Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/22e38345-b052-4cc3-a4c3-556e798109f3/small/pluristyx-logo-blue-apr22-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290254-fennec-pharmaceuticals-announces-investigator-sponsored-study-to-be-conducted-by-university-of-arizona-cancer-center</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:03:00+00:00</news:publication_date>
        <news:title>Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/2eeb9b85-0beb-4bbe-a7af-1c0e9403db44/small/fennec-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290176-invivyd-launches-antibodies-for-any-body-in-partnership-with-world-champion-skier-lindsey-vonn-to-inspire-actions-that-help-support-immune-health</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:01:00+00:00</news:publication_date>
        <news:title>Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290028-ac-immune-announces-amendment-to-morphomer-tau-license-and-collaboration-agreement-with-lilly</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290055-mediwound-to-present-new-escharex-data-at-leading-wound-care-conferences</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>MediWound to Present New EscharEx® Data at Leading Wound Care Conferences </news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/55509183-b8b9-4da4-ae63-92c83760b5d9/small/mdwd-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290057-radiopharm-theranostics-and-siemens-healthineers-sign-clinical-supply-agreement-for-rad101-in-the-u-s</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/8e246920-183e-46a4-b13c-a3c9ec50ada9/small/radx-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290245-sionna-therapeutics-to-participate-in-the-raymond-james-2026-biotech-innovation-symposium</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/0cda8c25-e758-4f0d-86f2-875df8411a9a/small/sionna-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290255-soleo-health-relocates-denver-specialty-pharmacy-to-support-continued-growth</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Soleo Health Relocates Denver Specialty Pharmacy to Support Continued Growth</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290282-breckenridge-distillery-introduces-honey-whiskey-crafted-with-rare-nigerian-goldswarm-honey-a-must-try-for-whiskey-enthusiasts</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Breckenridge Distillery Introduces Honey Whiskey Crafted with Rare Nigerian Goldswarm Honey—A Must-Try for Whiskey Enthusiasts</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/cb623008-0c9a-49db-ab38-6e3062dd8bdb/medium/breckenridge-distillery-honey-whiskey.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290354-climb-bio-announces-fda-fast-track-designation-for-budoprutug-for-the-treatment-of-primary-membranous-nephropathy</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/2a42b557-6e44-4818-bfce-2238a05f2c43/small/climb-400x400-002-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290361-skye-bioscience-presenting-at-glp-1-based-therapeutics-summit</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/905e06d8-af43-4f7a-b097-8c12ce1d3aa0/small/skye-darkblue-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290381-nurix-therapeutics-to-participate-in-upcoming-investor-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Nurix Therapeutics to Participate in Upcoming Investor Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/65f50366-0a4e-4329-b0f5-f737c6145524/small/new-primary-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290410-fortrea-unveils-fortrea-intelligent-technology-to-help-sponsors-and-sites-run-smarter-more-integrated-trials</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/9fbbe00b-8782-464e-83e6-5843c563884a/small/fortrea-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290597-neuronetics-comments-on-letter-from-pointillist-family-office</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Neuronetics Comments on Letter from Pointillist Family Office</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290600-okyo-pharma-announces-scientific-advisory-board-meeting-and-urcosimod-data-presentation-during-ascrs-annual-meeting</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/23e4046d-dcf9-4dd1-945e-461e98a27d15/small/full-logo-okyo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290602-vantage-hemp-co-engages-acos-and-gpos-to-advance-participation-in-cms-cbd-pilot-program</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T11:00:00+00:00</news:publication_date>
        <news:title>Vantage Hemp Co. Engages ACOs and GPOs to Advance Participation in CMS CBD Pilot Program</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/d38e4562-945b-4df7-8869-623c43be10f1/medium/inside-vantages-manufacturing-facility.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290206-ani-pharmaceuticals-announces-publication-of-new-day-clinical-trial-results-in-ophthalmology</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T10:50:00+00:00</news:publication_date>
        <news:title>ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904290397-bluejay-diagnostics-inc-announces-completion-of-624-patient-enrollments-in-symon-ii-pivotal-clinical-trial</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T10:30:00+00:00</news:publication_date>
        <news:title>Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/d0d4a766-5115-448d-ba8a-d522100949f1/small/bjdx-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904280802-serina-therapeutics-to-present-at-the-5th-lnp-formulation-process-development-summit</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T10:00:00+00:00</news:publication_date>
        <news:title>Serina Therapeutics to Present at the 5th LNP Formulation &amp; Process Development Summit</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/7f8e4304-8465-4d4d-a7e3-ebc4eae51f29/small/yellow-burts-blue-text-1-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904280810-ascellahealth-named-to-financial-times-americas-fastest-growing-companies-2026-list</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T10:00:00+00:00</news:publication_date>
        <news:title>AscellaHealth Named to Financial Times Americas’ Fastest Growing Companies 2026 List</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/5278c55f-330c-41a1-8446-d8b1a07bbc55/small/ah-logo-colornotag-4x-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904280821-greenwich-lifesciences-provides-update-on-patent-claims-potentially-doubling-gp2-market-potential</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T10:00:00+00:00</news:publication_date>
        <news:title>Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904263002-oculis-to-participate-in-upcoming-investor-conferences</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T08:00:00+00:00</news:publication_date>
        <news:title>Oculis to Participate in Upcoming Investor Conferences</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/f6fa6e90-83a4-4baa-a3b6-5483017d26b9/small/oculis-logo-gradient-jpg-resized-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904253341-sononeu-exits-stealth-as-key-part-of-us-government-funded-research-program-worth-up-to-41-3m-to-advance-sonogenetics-into-clinic</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T07:00:00+00:00</news:publication_date>
        <news:title>SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/28b90f6b-ca31-4be4-92ca-1d1e341f55f3/small/sononeu-small-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904235360-press-release-sanofi-s-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T05:00:00+00:00</news:publication_date>
        <news:title>Press Release:  Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP </news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904235375-communiqu-de-presse-le-lunsekimig-de-sanofi-a-atteint-les-crit-res-d-valuation-principal-et-secondaires-cl-s-dans-les-tudes-respiratoires-de-phase</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T05:00:00+00:00</news:publication_date>
        <news:title>Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904203057-memogenesis-claims-evaluated-researching-the-latest-memo-genesis-formulation-facts</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T01:10:16+00:00</news:publication_date>
        <news:title>MemoGenesis Claims Evaluated: Researching the Latest Memo Genesis Formulation Facts</news:title>
      </news:news>
        <image:image>
          <image:loc>https://zingfast.com/wp-content/uploads/2026/04/MemoGenesis.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904203030-ryoncil-continues-successful-first-year-launch-with-net-sales-of-us-30-3m-in-march-quarter</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-07T01:03:58+00:00</news:publication_date>
        <news:title>Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/a9938a8a-a0ba-4708-abd5-2219515343fc/small/mesologo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904187967-q1-2026-strong-revenue-growth-and-therapeutics-pipeline-advancement</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T23:37:15+00:00</news:publication_date>
        <news:title>Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904187944-organogenesis-achieves-primary-endpoint-in-randomized-controlled-trial-of-puraply-am</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T23:02:29+00:00</news:publication_date>
        <news:title>Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/9c2f551f-b7b2-403a-bf43-78f1889401e5/small/organogenesis-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904174110-renovare-therapeutics-inc-announces-company-launch-and-collaboration-with-cu-boulder-awardee-of-up-to-33-5-million-in-arpa-h-funding-to-advance</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T21:59:37+00:00</news:publication_date>
        <news:title>Renovare Therapeutics, Inc. Announces Company Launch and Collaboration with CU Boulder Awardee of up to $33.5 Million in ARPA-H Funding to Advance Osteoarthritis Regenerative Therapies</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/OTA0OGZiNjgtYTYzNi00MDUzLTk4YmYtYTMwMzBjYjVjMmNmLTEzMjIzODItMjAyNi0wNC0wNi1lbg==/tiny/Renovare-Therapeutics-Inc-.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904173827-avicanna-announces-changes-to-its-board-of-directors</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T21:30:00+00:00</news:publication_date>
        <news:title>Avicanna Announces Changes to its Board of Directors</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/c9abc2f4-efdc-40f6-921d-a5da048eda46/small/avicanna-logo-colour-withtm-01-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904173889-organogenesis-announces-successful-fda-meeting-and-plan-to-file-bla-for-renu-for-knee-osteoarthritis-pain</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T21:30:00+00:00</news:publication_date>
        <news:title>Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/9c2f551f-b7b2-403a-bf43-78f1889401e5/small/organogenesis-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904167591-metabo-drops-claims-evaluated-recent-investigation-into-metabodrops-official-website-announcement</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T21:16:34+00:00</news:publication_date>
        <news:title>Metabo Drops Claims Evaluated: Recent Investigation Into MetaboDrops Official Website Announcement</news:title>
      </news:news>
        <image:image>
          <image:loc>https://zingfast.com/wp-content/uploads/2026/04/Metabo-Drops.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904161943-neuronetics-announces-chief-financial-officer-transition</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T20:30:00+00:00</news:publication_date>
        <news:title>Neuronetics Announces Chief Financial Officer Transition</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904162001-glyco-harmony-drops-claims-evaluated-explore-the-official-gluco-harmony-glycogen-support-website-facts</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T20:21:12+00:00</news:publication_date>
        <news:title>Glyco Harmony Drops Claims Evaluated: Explore the Official Gluco Harmony Glycogen Support Website Facts</news:title>
      </news:news>
        <image:image>
          <image:loc>https://zingfast.com/wp-content/uploads/2026/04/Glyco-Harmony-Drops.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904161867-silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T20:15:00+00:00</news:publication_date>
        <news:title>Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/3b635464-4382-4b8b-8175-39cc32e08050/small/logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904161146-outset-medical-names-derick-elliott-as-executive-vice-president-of-commercial</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T20:05:00+00:00</news:publication_date>
        <news:title>Outset Medical Names Derick Elliott as Executive Vice President of Commercial</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/28778c78-03f1-4b17-9c13-3cc578c924dc/small/outset-id-orangegrey-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904161822-nanox-to-report-fourth-quarter-2025-financial-results-on-april-20-2026</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T20:05:00+00:00</news:publication_date>
        <news:title>Nanox to Report Fourth Quarter 2025 Financial Results on April 20, 2026</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904161913-immuneering-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T20:05:00+00:00</news:publication_date>
        <news:title>Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/81d0c83f-ae53-4d6e-9c5e-d6963e02f29d/small/immuneering-logo-cropped-1-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904161866-dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T20:01:00+00:00</news:publication_date>
        <news:title>Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/c9002285-2240-4dab-aced-77296f86a3fa/small/dianthus-logo-primary-full-color-cmyk-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904161983-ascendis-receives-orphan-drug-exclusivity-and-launches-yuviwel-navepegritide-in-the-united-states</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T20:01:00+00:00</news:publication_date>
        <news:title>Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/b4b7c29a-478e-4a8e-b23b-b6a1cb18aee8/small/ascendis-final-logo-7-23-15-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904161906-cytokinetics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T20:00:00+00:00</news:publication_date>
        <news:title>Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/52e2be9f-e9e3-43af-a747-123fdcac4253/small/cytokinetics-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904149403-mistr-founder-tristan-schukraft-joins-the-producing-team-of-titanique</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T19:00:00+00:00</news:publication_date>
        <news:title>MISTR Founder Tristan Schukraft Joins the Producing Team of Titanique</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/NjA1ZGExYWItMDMwMC00NGI5LTk1ZTItM2NjNmIzZWNjZmNjLTUwMDEzNDg1Ny0yMDI2LTA0LTA2LWVu/tiny/MISTR.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904149512-glucozen-claim-evaluated-highly-effective-blood-sugar-support-for-natural-glucose-harmony</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T18:40:44+00:00</news:publication_date>
        <news:title>GlucoZen Claim Evaluated: Highly-Effective Blood Sugar Support for Natural Glucose Harmony</news:title>
      </news:news>
        <image:image>
          <image:loc>https://zingfast.com/wp-content/uploads/2026/04/GlucoZen-Drops.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904143857-global-validation-calibration-and-standardization-in-life-sciences-market-to-reach-3-9-billion-by-2030-fueled-by-regulatory-demands-and-digital</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T18:00:00+00:00</news:publication_date>
        <news:title>Global Validation, Calibration and Standardization in Life Sciences Market to Reach $3.9 Billion by 2030, Fueled by Regulatory Demands and Digital Transformation</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904143771-wellspan-health-announces-president-ceo-roxanna-gapstur-s-planned-retirement</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T17:49:26+00:00</news:publication_date>
        <news:title>WellSpan Health announces President &amp; CEO Roxanna Gapstur’s planned retirement</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/NGE2MDdiZGQtMzEyMy00NmIxLWE0ZTUtM2JmODBmOTQyOTg1LTEyMjE1MzQtMjAyNi0wNC0wNi1lbg==/tiny/WellSpan-Health.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904138873-dibs-ai-unveils-version-9-0-platform-suite-to-streamline-orthodontic-workflows</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T17:30:00+00:00</news:publication_date>
        <news:title>DIBS AI Unveils Version 9.0 Platform Suite to Streamline Orthodontic Workflows</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/NzhmMTE3NzktZTQ1MS00OWY2LTkzMDgtZjAzYmU3OTY3YWI2LTEyMTI1MjAtMjAyNi0wNC0wNi1lbg==/tiny/OrthoSelect.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904129544-mistr-covers-florida-patients-as-adap-changes-create-gaps-in-hiv-treatment-access</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T16:14:44+00:00</news:publication_date>
        <news:title>MISTR Covers Florida Patients as ADAP Changes Create Gaps in HIV Treatment Access</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/YTc5NzBiN2ItNDFmYy00MjgxLWJkOGYtMWVmZjk2ODRiM2JkLTUwMDEzNDg1Ny0yMDI2LTA0LTA2LWVu/tiny/MISTR.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904124434-biodesix-announces-aacr-2026-posters-and-presentations-highlighting-novel-diagnostic-test-discovery-pipeline-development</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T15:43:00+00:00</news:publication_date>
        <news:title>Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery &amp; Pipeline Development</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/b2fd8e3c-ff04-47d9-938d-93c9c961ccc3/small/bdsx-logo-1200x240-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904119613-yuzu-health-raises-35-million-series-a-to-modernize-health-insurance-plan-infrastructure</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T15:00:00+00:00</news:publication_date>
        <news:title>Yuzu Health Raises $35 Million Series A to Modernize Health Insurance Plan Infrastructure</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/ZTNkMDYxNWQtZmVjYS00M2RlLWI0OWYtMzA2MGY0YjhlN2E2LTEzMjIzODUtMjAyNi0wNC0wNi1lbg==/tiny/Yuzu-Health.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904119642-hairclub-launches-100-000-aderans-helping-hearts-fund-to-support-employees-facing-life-s-unexpected-hardships</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T15:00:00+00:00</news:publication_date>
        <news:title>HairClub Launches $100,000 Aderans Helping Hearts Fund to Support Employees Facing Life’s Unexpected Hardships</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/MDFmYjQwOTktMzE2MS00NTQ1LWI0ZDMtN2I4OWM2NDJjYzZjLTUwMDE1MzY4OS0yMDI2LTA0LTA2LWVu/tiny/HairClub.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904119717-celldex-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T14:53:52+00:00</news:publication_date>
        <news:title>Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904115336-sienna-senior-living-recognized-by-the-globe-and-mail-s-women-lead-here-benchmark</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T14:25:00+00:00</news:publication_date>
        <news:title>Sienna Senior Living recognized by The Globe and Mail’s Women Lead Here Benchmark</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904111237-al-anon-family-groups-celebrates-75-years-of-recovery-providing-help-and-hope-to-families</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T14:00:00+00:00</news:publication_date>
        <news:title>Al‑Anon Family Groups Celebrates 75 Years of Recovery — Providing Help and Hope to Families</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/293e2cf1-ce41-48e5-a66c-8a69496d5d01/small/al-anon-family-groups-logo.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904111343-adaptin-bio-shares-to-be-quoted-on-the-otcqb-under-ticker-symbol-aptn</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T14:00:00+00:00</news:publication_date>
        <news:title>Adaptin Bio Shares to be Quoted on the OTCQB Under Ticker Symbol APTN</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/89fb59f4-0171-4319-995d-70be0b36378b/small/logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904107243-9-66-bn-gastroenterology-products-market-forecasts-to-2034-rising-aging-population-advancing-endoscopic-tech-and-expanding-healthcare-in</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:29:11+00:00</news:publication_date>
        <news:title>$9.66+ BN Gastroenterology Products Market Forecasts to 2034: Rising aging population, advancing endoscopic tech, and expanding healthcare in developing regions</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/1f4cf0ab-7d76-4136-a6dc-a5545f80f538/small/zion-market-research-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904107250-zhengye-biotechnology-holding-limited-announces-implementation-of-dual-class-share-structure</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:25:00+00:00</news:publication_date>
        <news:title>Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/9f44f819-7666-4ef0-b9e0-d50035c2a412/small/zybt-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904107196-curanex-highlights-patient-case-study-supporting-potential-of-phyto-n-in-cancer-cachexia-and-advanced-cancer-supportive-care</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:17:00+00:00</news:publication_date>
        <news:title>Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/29bc3de5-6a82-4a17-a165-6a79eef16d74/small/logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103439-egg-medical-launches-eggnest-complete-flex-apron-free-protection-without-construction-downtime-or-disruption</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical Launches EggNest™ Complete Flex: Apron-Free Protection Without Construction, Downtime or Disruption</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/14f028e0-82c4-433b-a70a-84b9ad7c33c6/medium/eggnest-complete-flex.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103443-oncolytics-biotech-announces-type-c-fda-meeting-to-discuss-single-arm-registrational-pathway-for-pelareorep-in-anal-cancer</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/4dca5efc-ee4e-4e0a-b42d-7b45369d75da/small/oncy-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103447-flare-therapeutics-announces-three-upcoming-poster-presentations-at-aacr-annual-meeting-2026</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Flare Therapeutics Announces Three Upcoming Poster Presentations at AACR Annual Meeting 2026</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/fbcb69a8-bb9a-4d13-b91e-c43f05ec2ee1/small/flaretx-logo-overlightbg-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103449-egg-medical-bringt-eggnest-complete-flex-auf-den-markt-schutz-ohne-sch-rzen-ohne-bauarbeiten-ausfallzeiten-oder-betriebsunterbrechungen</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical bringt EggNest™ Complete Flex auf den Markt: Schutz ohne Schürzen, ohne Bauarbeiten, Ausfallzeiten oder Betriebsunterbrechungen</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103453-egg-medical-lanza-eggnest-complete-flex-protecci-n-sin-delantal-sin-obras-ni-interrupciones</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical lanza EggNest™ Complete Flex: protección sin delantal, sin obras ni interrupciones</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103457-egg-medical-pr-sente-eggnest-complete-flex-une-protection-sans-tablier-sans-travaux-sans-interruption-de-service-ni-perturbation</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical présente EggNest™ Complete Flex : une protection sans tablier, sans travaux, sans interruption de service ni perturbation</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103458-egg-medical-eggnest-complete-flex</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical משיקה את EggNest™ Complete Flex: הגנה ללא סינר, ללא בנייה, השבתה או שיבושים</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103462-egg-medical-meluncurkan-eggnest-complete-flex-perlindungan-bebas-apron-tanpa-pekerjaan-konstruksi-waktu-henti-atau-gangguan</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical Meluncurkan EggNest™ Complete Flex: Perlindungan Bebas Apron Tanpa Pekerjaan Konstruksi, Waktu Henti, atau Gangguan</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103469-eggnest-complete-flex</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>エッグ・メディカル、エッグネスト・コンプリート・フレックス (EggNest™ Complete Flex) を発売: 工事や稼働停止、業務中断なく、エプロン不要の防護を実現</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103472-egg-medical-eggnest-complete-flex</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical, 별도 공사나 다운타임 없이 납 앞치마 불필요한 방사선 보호 솔루션 ‘EggNest™ Complete Flex’ 출시</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103474-egg-medical-lancarkan-eggnest-complete-flex-perlindungan-tanpa-apron-tanpa-keperluan-kerja-pembinaan-masa-henti-atau-gangguan</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical Lancarkan EggNest™ Complete Flex: Perlindungan Tanpa Apron Tanpa Keperluan Kerja Pembinaan, Masa Henti atau Gangguan</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103475-egg-medical-lan-a-eggnest-complete-flex-prote-o-sem-avental-sem-constru-o-tempo-de-inatividade-ou-interrup-o</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical Lança EggNest™ Complete Flex: Proteção Sem Avental, Sem Construção, Tempo de Inatividade ou Interrupção</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103507-egg-medical-eggnest-complete-flex</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical เปิดตัว EggNest™ Complete Flex รุ่นป้องกันแบบไม่ต้องใช้เสื้อป้องกัน โดยไม่ต้องมีการก่อสร้าง ไม่ต้องหยุดการดำเนินงาน และไม่ขัดจังหวะการทำงา…</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103509-egg-medical-eggnest-complete-flex</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical 推出 EggNest™ Complete Flex：无需施工、停机或中断即可实现无铅衣防护</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103516-egg-medical-eggnest-complete-flex</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Egg Medical 推出 EggNest™ Complete Flex：免穿鉛圍的防護解決方案，免工程、不停機、無中斷</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/25a59b3b-1200-4803-9e32-91553d4bc51c/small/egg-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103575-stress-awareness-month-signals-shift-away-from-always-on-living</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T13:00:00+00:00</news:publication_date>
        <news:title>Stress Awareness Month Signals Shift Away from “Always-On” Living</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/b847767e-6b43-48ae-ba24-0c320ae99e0f/medium/national-stress-awareness-month.jpeg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103552-onemednet-announces-strong-2025-financials-and-advances-ai-driven-irwd-powered-by-palantir-foundry-enabling-conversational-search-on-real-time</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:50:00+00:00</news:publication_date>
        <news:title>OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/a356ae1d-a3c0-49e3-81b5-f19be76513d0/small/onemednet-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904103518-akari-therapeutics-announces-strategic-partnership-with-wuxi-xdc-to-advance-development-of-its-novel-adc-payload-targeting-rna-splicing</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:45:00+00:00</news:publication_date>
        <news:title>Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904100059-abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635-c-4</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:30:00+00:00</news:publication_date>
        <news:title>Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904100065-stablecoin-development-corporation-begins-trading-on-nyse-american-under-ticker-sdev</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:30:00+00:00</news:publication_date>
        <news:title>Stablecoin Development Corporation Begins Trading on NYSE American Under Ticker “SDEV”</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/NDdlZTYyYTAtY2U1Ni00MzY2LWI2MTQtMDI5MDk0MDNhYjVkLTEwMjg2MTQtMjAyNi0wNC0wNi1lbg==/tiny/Stablecoin-Development-Corpora.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904100133-tomi-environmental-solutions-inc-announces-surge-in-steramist-adoption-across-compounding-pharmacy-industry-amid-tightening-regulatory-standards</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:30:00+00:00</news:publication_date>
        <news:title>TOMI Environmental Solutions, Inc. Announces Surge in SteraMist Adoption Across Compounding Pharmacy Industry Amid Tightening Regulatory Standards</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/f8c7c513-0121-4507-84b7-3680626d9cf3/small/tomi-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904100107-stereotaxis-announces-fda-clearance-and-launch-of-synchrony-system</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:06:00+00:00</news:publication_date>
        <news:title>Stereotaxis Announces FDA Clearance and Launch of Synchrony System</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/95a5b8ca-b7c0-4c80-8ca7-063ef10706c3/small/stereotaxis-logo-new-tagline-black-text-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904100079-scienture-provides-annual-shareholder-update-outlining-significant-progress-and-strategic-priorities-for-the-year-ahead</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:05:00+00:00</news:publication_date>
        <news:title>Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/56382978-c242-4bdd-b491-e6966e27d4ed/small/logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096500-geron-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096520-inspire-medical-systems-inc-to-report-first-quarter-2026-financial-results-on-may-4-2026</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Inspire Medical Systems, Inc. to Report First Quarter 2026 Financial Results on May 4, 2026</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/194e83a5-3f7e-4805-88ce-da2e0ab594df/small/inspire-primary-logo-rgb-daylight-002-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096550-avalyn-appoints-jon-congleton-seasoned-biopharmaceutical-executive-to-its-board-of-directors</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/84d7bff4-ce17-433b-8c71-aa20c30f9f43/small/avalyn-logo-final-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096557-verrica-pharmaceuticals-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b/small/verrica-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096615-aveanna-healthcare-announces-second-annual-aveanna-cares-month-of-service</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Aveanna Healthcare Announces Second Annual Aveanna Cares Month of Service</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/d3896f9e-a6a1-48c1-a8f7-d9ba5d7433d6/small/aveanna-healthcare-500x262-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096643-tenvie-therapeutics-announces-dosing-of-first-subject-in-phase-1-clinical-trial-of-tnv262-a-fully-cns-penetrant-nlrp3-inhibitor</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/311d9377-979c-4384-9258-5b496e854edb/small/tenvie-logo-gradient-rgb-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096651-phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/0baa6f51-c6cb-4b21-a4e0-573a18b8171c/small/phathom-pharm-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096655-praxis-precision-medicines-announces-positive-results-from-the-embrave-part-a-trial-of-elsunersen-in-patients-with-scn2a-early-onset-developmental-and</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096727-anna-autism-care-appoints-ariana-boutain-phd-bcba-d-as-chief-clinical-officer</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>ANNA Autism Care Appoints Ariana Boutain, PhD, BCBA-D as Chief Clinical Officer</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/NWMwMTNkZjMtYTQwYi00YjY3LTkzNjctOWU3ZGMyZTY3Y2ZiLTEzMjA4ODAtMjAyNi0wNC0wNi1lbg==/tiny/ANNA-HEALTH-INCORPORATED.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096753-new-locket-data-accepted-in-leading-electrophysiology-journal</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>New LockeT Data Accepted in Leading Electrophysiology Journal</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096759-extendicare-announces-timing-of-2026-first-quarter-results-and-conference-call</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Extendicare Announces Timing of 2026 First Quarter Results and Conference Call</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/6d631964-eede-4e2c-912c-58ab7d1dc35f/small/extendicare-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904096792-axe-compute-names-kyle-okamoto-president-adding-deep-infrastructure-systems-expertise-to-executive-team</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T12:00:00+00:00</news:publication_date>
        <news:title>Axe Compute Names Kyle Okamoto President, Adding Deep Infrastructure Systems Expertise to Executive Team</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/0722059f-4d31-435e-974f-ff669a2cb2e4/small/axe-compute.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904092950-organogenesis-holdings-inc-to-report-first-quarter-of-fiscal-year-2026-financial-results-on-may-7-2026</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:30:00+00:00</news:publication_date>
        <news:title>Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/9c2f551f-b7b2-403a-bf43-78f1889401e5/small/organogenesis-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904092960-medicus-pharma-submits-optimized-phase-2-study-protocol-to-u-s-fda-for-teverelix-in-acute-urinary-retention</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:30:00+00:00</news:publication_date>
        <news:title>Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/0f5af1d1-dfba-4810-baac-d1922c0558c1/small/medicus-logo-rgb-05-aspect-1500px-globe-newswire-2-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904092976-kraig-biocraft-laboratories-shatters-production-record-delivering-over-1-3-metric-tons-of-spider-silk-cocoons-in-a-single-month-a-5x-increase-over</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:05:00+00:00</news:publication_date>
        <news:title>Kraig Biocraft Laboratories Shatters Production Record, Delivering Over 1.3 Metric Tons of Spider Silk Cocoons in a Single Month, A 5X Increase Over Previous High</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/bd9626d2-4b5e-4f55-8b54-c8300fa5bef5/medium/bam1-recombinant-spider-silk-cocoons.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089915-invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:01:00+00:00</news:publication_date>
        <news:title>Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089912-stipple-bio-emerges-from-stealth-with-oversubscribed-100-million-series-a-financing-to-advance-stp-100-into-early-clinical-studies-and-advance-a</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/96c458bd-cad2-4343-89d4-8c60bcfde0a5/small/stipple-no-name-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089917-biocryst-appoints-sandeep-m-menon-chief-research-and-development-officer</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089923-sagimet-biosciences-announces-poster-and-oral-presentations-at-the-fueling-mash-metabolic-drivers-and-inflammatory-crosstalk-keystone-symposium-and</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/e944daed-3f71-402b-bb23-82149e5c0d26/small/sagimet-logo-for-light-bg-fin-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089924-immunocore-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference  </news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml-eu.globenewswire.com/media/bcaafaab-2536-4b4b-899c-9913925b6e4b/small/immunocore-logo-2018.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089932-agios-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-april-29-at-8-00-a-m-et</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/c7d64dad-71c8-47cc-a58d-c93a49ce8f01/small/agios-2021-logo-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089955-opus-genetics-solidifies-leadership-position-in-gene-therapy-development-for-inherited-retinal-diseases-with-strategic-long-term-financing-by-oberland</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/468baef1-3b2d-4353-a17e-cb41b45ee6ef/small/opus-rgb-r-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089957-nrx-pharmaceuticals-nasdaq-nrxp-announces-fda-labeling-alignment-for-nrx-s-preservative-free-ketamine-application</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089969-sharps-technology-reports-2025-year-end-results-and-highlights-continued-execution-of-solana-treasury-strategy</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/7e8b9bfa-42f5-446c-932a-41a01c25ed6b/small/sharps-technology-nasdaq-stss-white-background-png.png</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904089975-neumora-therapeutics-to-participate-in-25th-annual-needham-virtual-healthcare-conference</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T11:00:00+00:00</news:publication_date>
        <news:title>Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/48256578-6cd3-4332-bf9b-2f52cfa248b7/small/neumora-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904086918-beacon-biosignals-upsizes-series-b-financing-to-over-97-million</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T10:30:00+00:00</news:publication_date>
        <news:title>Beacon Biosignals Upsizes Series B Financing to Over $97 Million</news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/0485bb01-d362-473e-8fae-a6cab3b804aa/small/beacon-logo-inline-1-jpg.jpg</image:loc>
        </image:image>
    </url>
    <url>
      <loc>https://www.vaticanhealthtimes.com/article/904084259-profusa-expands-into-multi-billion-dollar-precision-diagnostics-market-with-30m-letter-of-intent-for-a-panomics-platform</loc>
      <news:news>
        <news:publication>
          <news:name>Vatican Health Times</news:name>
          <news:language>en</news:language>
        </news:publication>
        <news:genres>PressRelease</news:genres>
        <news:publication_date>2026-04-06T10:00:00+00:00</news:publication_date>
        <news:title>Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform </news:title>
      </news:news>
        <image:image>
          <image:loc>https://ml.globenewswire.com/media/a8137a61-b858-48da-9e47-1f1bf8f6ddba/small/profusa-logo-jpg.jpg</image:loc>
        </image:image>
    </url>
</urlset>
